Kleybanova Named Comeback Tennis Player of the Year
The World Tennis Association (WTA) has announced its Comeback Player of the Year award for 2013. The winner is Alisa Kleybanova, the young Russian woman diagnosed with Hodgkin's lymphoma in 2011.
Kleybanova was a top 20-ranked tennis player when she received the diagnosis in 2011. Although she would take part in a WTA event in 2012 following completion of her treatment, it was the only event of the year for her. She spent the remainder of that time recovering and preparing herself for the tour.
A positive comeback
This year, Kleybanova has found her way all the way back to the tour, first competing in international federation events before playing WTA events in Moscow, Toronto, Cincinnati and the U.S. Open.
She won four of her eight WTA matches while also playing in the Fed Cup for Russia.
Said Kleybanova:
I just have to stay positive about things, have a nice off-season, train hard, stay healthy, stay away from injuries, and just have a good preparation over the next weeks to get ready for the new season. And after that, I hope to play the 2014 season from the first month to the last month.
Source: WTA
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
